Ukunyanzeliswa kwe-Atypical Is Real Very Common

Ukuchaneka unyango kunokuxhomekeka kwisifo esilungileyo

Ukongeza kwiimpawu eziphambili zokudakumba , ukuxinezeleka kwe- atypical kuchazwa ngokukwazi ukuziva ulunge okwethutyana xa usabela kwisiganeko sokuphila esilungileyo, kunye neyiphi na imigaqo elandelayo: ukulala ngokweqile, ukunyamezela, ukuziva uxinzelelo kwimilenze kunye novelwano ukugatywa.

Izigulane ezinokudakumba zintlungu ziba nobudala bokuqala kunezo zinezinye iincinci ngoba kuqala zivela kwiminyaka yeshumi elivisayo.

Ezi zi gulane nazo ziyakwazi ukuba neembali zentlalo yoluntu , ukuziphatha okukhuselekileyo kunye nembali yomzimba wesifo se-dysmorphic disorder .

Ziyinto Eqhelekileyo Yokuxinezeleka Kwama-Atypical?

Ngaphandle kwegama, ukuxinezeleka kwangokwemvelo kuyona yinto eqhelekileyo yokuxinezeleka, ngokutsho kukaDkt. Andrew A. Nierenberg, umlawuli onxulumene nenkxalabo yokudandatheka kunye neprogram yophando eMassachusetts General Hospital, eBoston. Ngophando luka-1998, yena kunye nabahlobo bakhe bafumene ukuba i-42% yabathathi-nxaxheba babenengxaki yokudandatheka, i-12% yayinexinezelekile, i-14% yayineengcinezelo zengcinezelo, kwaye abanye babengenalo. "Kuqhelekile kunokuba sonke sicinga. Akungabazeki ukuba siyaziqonda," kusho uDkt. Nierenberg.

Unyango

Ukwenza utyilongo oluchanekileyo lwale subtype kubaluleke kakhulu ekuboneleleni isigulane ngonyango olusebenzayo. Nangona i-serotonin i-reuptake inhibitors (i-SSRIs) kunye neminye imishanguzo emitsha ngokuqhelekileyo iyona ndlela yokuqala yokukhetha unyango lokudakumba ngenxa yeempembelelo zabo zecala-impembelelo, izigulane ezinexinzelelo zentlungu zivame ukuphendula kangcono kwi- monoamine oxidase inhibitors (MAOIs).

Nangona kunjalo, i-SSRI inokumiselwa kuqala ngenxa yokuba ayinayo imiphumo emibi okanye imingcipheko yokutya e-MAOIs.

Kuyathakazelisa ke, nangona kunjalo, unyango lweziyobisi lungafaneleki nhlobo. Uphando oluqhutywe ngo-1999 lwafumanisa ukuba izigulane ezifumana unyango lwe-cognitive-behavioral (CBT) zaphendule kanye nezigulane ezifumana i-MAOI phenelzine.

I-58% yezigulane kumabini omabili asabela, xa kuthelekiswa ne-28% kuphela yezigulane kwiqela le-placebo.

Olunye uphando oluqhutywe ngo-2015 lubonise ukuba iimiphumo zonyango zesibini zokuzala izidakamizwa kunye ne-CBT, mhlawumbi ngokwahlukileyo okanye kunye kunye, zifana nezigulane ezineengxaki ezinkulu zokudandatheka. Kucacile ukuba uphando olungakumbi lufuneka lwenziwe kulo.

Ukuba Ucinga Ukuba Unesifo Sokuxinezeleka

Kubalulekile ukubona umculi wezifo zengqondo kunokuba ugqirha wakho wokunonyango unyango. Akunabo bonke abaphambukileyo abafanayo okanye abaphenduliyo kumachiza afanayo. Ugqirha ngokuqhelekileyo akakwazi ukuba namava afanelekileyo ukuze ahlule phakathi kwamagqabantshintshi okudakumba okanye ukwazi ukuba zeziphi ukhetho lwezokwelapha olunokwenzeka ukuba lusebenze. Unokubandezeleka ngokungenasidingo njengoko ugqirha uzama onke amayeza angalunganga. Ngenxa yokuba uqobo lwengxaki yokuxinezeleka, oku kuhambanisa kuphela iimvakalelo zakho ezidandathekile.

Ukuba unyanzelekile nge-inshurensi okanye kwiimeko zemali ukuba ubone ugqirha wokunakekelwa ngonyango kunyango lwakho, kufuneka wenze lo myalelo ukwenza ulwaphulo olunokwenzeka kwilwazi lwakho. Oku akufani nokuba kunjalo, ngokuqinisekileyo, kodwa de kubekho utshintsho olukhulu kwiinkqubo zethu zononophelo lwezempilo, kunokufuneka.

Ukuba uyazifundisa kwaye uthatha indima ebalulekileyo kwonyango, awukwazi ukuba utyumle ukutyhulwa kwezifo.

Imithombo:

I-Clinical Psychiatry IiNdaba 26 (12): 25, 1998.

Umbhalo we-Clinical Psychiatry 59 I-Suppl 18: 5-9, 1998.

I-American Journal ye-Psychiatry 157 (3): 344-350, ngoMatshi 2000.

IiNqoloba zoLwazi lweeNzululwazi 56 (5): 431-47, Meyi 1999.

U-Singh, T. noWilliam, K. "Ukunyanzeliswa kweAtypical." I-Psychiatry MMC, 3 (4), 2006.

" Izibonelelo ezinokuqhathaniswa kunye nezigwenxa zentsholongwane yokuhlukumeza izizukulwana zesibini kunye neendlela zokuziphatha ezinokwenziwa kwengqondo kwindlela yokuqala yokunyangwa kwengxaki yokudandatheka: ukuhlolwa kweenkqubo kunye nokuhlaziywa kwemeta." BMJ 2015; 351: h6019.